EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SARS‐CoV‐2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era: Input for Future Response

Eric R A Vos iD, Cheyenne C E van Hagen, Denise Wong, Gaby Smits, Marjan Kuijer, Alienke J Wijmenga-Monsuur, Joanna Kaczorowska, Robert S van Binnendijk, Fiona R M van der Klis, Gerco den Hartog iD, Hester E de Melker

Influenza and Other Respiratory Viruses · 2024-06 · 18 (6)

DOI: 10.1111/irv.13312 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, online erschienen am 04.06.2024. Verfasst von Eric R A Vos und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Epidemiology and Surveillance, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bil…. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Antibodies, Viral. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Welfare and Sport (VWS) in the Netherlands.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To inform future response planning we aimed to assess SARS‐CoV‐2 trends in infection‐ and/or vaccine‐induced immunity, including breakthrough infections, among (sub)groups, professions and regions in the Dutch population during the Variant of Concern (VOC)‐era.

Methods

In this prospective population‐based cohort, randomly selected participants ( n = 9985) aged 1–92 years (recruited early‐2020) donated home‐collected fingerstick‐blood samples at six timepoints in 2021/2022, covering waves dominated by Alpha, Delta, and multiple Omicron (sub‐)variants. IgG antibody assessment against Spike‐S1 and Nucleoprotein was combined with vaccination‐ and testing data to estimate infection‐induced (inf) and total (infection‐ and vaccination‐induced) seroprevalence.

Results

Nationwide inf‐seroprevalence rose modestly from 12% (95% CI 11–13) since Alpha to 26% (95% CI 24–28) amidst Delta, while total seroprevalence increased rapidly to 87% (95% CI 85–88), particularly in elderly and those with comorbidities (i.e., vulnerable groups). Interestingly, highest infection rates were noticeable among low/middle educated elderly, non‐Western, those in contact professions, adolescents and young adults, and in low‐vaccination coverage regions. Following Omicron emergence, inf‐seroprevalence elevated sharply to 62% (95% CI 59–65) and further to 86% (95% CI 83–90) in late‐2022, with frequent breakthrough infections and decreasing seroprevalence dissimilarities between most groups. Whereas > 90% of < 60‐year‐olds had been infected at least once, 30% of vaccinated vulnerable individuals had still not acquired hybrid immunity.

Conclusions

Groups identified to have been infected disproportionally during the acute phase of the pandemic require specific attention in evaluation of control measures and future response planning worldwide. Furthermore, ongoing tailored vaccination efforts and (sero‐)monitoring of vulnerable groups may remain important.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2Antibodies, ViralHumansSeroepidemiologic StudiesNetherlandsMiddle AgedAdolescentAdultAgedChildChild, PreschoolYoung AdultMaleFemaleAged, 80 and overInfantProspective StudiesCOVID-19 VaccinesImmunoglobulin GVaccination

Stichwörter der Autor:innen

COVID‐19SARS‐CoV‐2breakthrough infectionspandemic preparednessprospective cohortrisk groupsseroprevalence trendsthe Netherlands

Substanzen

Antibodies, ViralCOVID-19 VaccinesImmunoglobulin G

Autor:innen und Institutionen

  • Centre for Epidemiology and Surveillance, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
  • Centre for Immunology of Infectious Diseases and Vaccines, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
  • Laboratory of Medical Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen, The Netherlands.

ORCID-Profile: Eric R A Vos, Gerco den Hartog

Förderung

  • Ministry of Health, Welfare and Sport (VWS) in the Netherlands

Zitieren

APA

Vos, E. R. A., van Hagen, C. C. E., Wong, D., Smits, G., Kuijer, M., Wijmenga-Monsuur, A. J., Kaczorowska, J., van Binnendijk, R. S., van der Klis, F. R. M., den Hartog, G., & de Melker, H. E. (2024). SARS‐CoV‐2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era: Input for Future Response. Influenza and Other Respiratory Viruses, 18(6). https://doi.org/10.1111/irv.13312

Vancouver

Vos ERA, van Hagen CCE, Wong D, Smits G, Kuijer M, Wijmenga-Monsuur AJ, et al. SARS‐CoV‐2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era: Input for Future Response. Influenza and Other Respiratory Viruses. 2024;18(6). doi:10.1111/irv.13312

BibTeX
@article{Vos2024,
  author = {Vos, Eric R A and van Hagen, Cheyenne C E and Wong, Denise and Smits, Gaby and Kuijer, Marjan and Wijmenga-Monsuur, Alienke J and Kaczorowska, Joanna and van Binnendijk, Robert S and van der Klis, Fiona R M and den Hartog, Gerco and de Melker, Hester E},
  title = {SARS‐CoV‐2 Seroprevalence Trends in the Netherlands in the Variant of Concern Era: Input for Future Response},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  volume = {18},
  number = {6},
  doi = {10.1111/irv.13312}
}
Kostenlos starten →